Company intelligence / Profile preview

SENDO TECH

San Francisco, California, USA

Ownership: Private
Development stage: Other

Overview

Sendo is an AI-driven biotechnology company focused on the discovery and development of therapeutics targeting cellular senescence. By leveraging machine learning and high-throughput screening, the company identifies novel senolytics and senomorphics designed to clear or modulate senescent cells, which are key drivers of aging and chronic disease. Sendo's platform aims to accelerate the drug discovery process for age-related conditions, including fibrosis and metabolic disorders. The company operates at the intersection of longevity science and computational biology to address the root causes of biological aging.

Therapeutic areas: OtherMetabolic DisordersImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on SENDO TECH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SENDO TECH.

Explore the full profile